Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
CONy 2023
ACTRIMS 2023
ISC 2023
EHC 2022
AES 2022
WSC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Dalia Rotstein
2:18
Predictors of early serologic diagnosis of AQ4-IgG positive NMOSD
Dalia Rotstein
• 27 Oct 2022
0:47
When to make a timely switch to high-efficacy DMT for MS
Dalia Rotstein
• 27 Oct 2022
1:40
Proportion of life and incidence of MS in Canadian immigrants
Dalia Rotstein
• 27 Oct 2022
2:12
When to consider an escalation approach for MS treatment
Dalia Rotstein
• 27 Oct 2022
2:50
Chronic cognitive impairment improved after eculizumab initiation in cases of NMOSD
Dalia Rotstein
• 25 Feb 2022
2:28
Is EBV the main cause of MS onset?
Dalia Rotstein
• 25 Feb 2022
2:07
Prognostic factors in NMOSD: age, ethnicity, and relapse history
Dalia Rotstein
• 8 Oct 2021
1:30
Key research questions in seronegative NMOSD
Dalia Rotstein
• 8 Oct 2021
3:18
Identifying risk factors for AQP4+ NMOSD
Dalia Rotstein
• 8 Oct 2021
4:03
The predictive value of NEDA-3 for long-term disability in MS
Dalia Rotstein
• 8 Oct 2021
1:17
Improving educational opportunities for neurology residents globally
Dalia Rotstein
• 16 Feb 2021
1:34
The impact of social networks on physical impairment in MS
Dalia Rotstein
• 16 Feb 2021
2:51
No evidence of disease activity as a predictive measure of long-term disability in RRMS
Dalia Rotstein
• 16 Feb 2021
2:17
What to look out for at ACTRIMS 2021
Dalia Rotstein
• 16 Feb 2021